Clinical trials: Bone Metastases From Solid Tumors
Bone Metastasis From Solid Tumors
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
A randomized, double-blind and parallel group study to compare the pharmacokinetic, pharmacodynamic, safety and immunogenicity of HS-20090 120mg（1.7ml）and Xgeva® in healthy adults.
- Trial name
- NCT04494373
- Testing
- HS-20090, Xgeva®
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bone Metastases From Solid Tumors
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
- Trial name
- NCT04630522
- Testing
- Drug: JMT103- 120 mg SC Q4W, Drug: JMT103- 120 mg SC Q8W, Drug: JMT103- 180 mg SC Q8W
- Where
- China
- Volunteers
- 295 people
- Sponsor
- Shanghai JMT-Bio Inc.
Bone Metastases
To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, comparative study to evaluate the clinical efficacy and safety of QL1206 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04550949
- Testing
- QL1206, Xgeva
- Where
- 2 sites in China
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with…
- Trial name
- NCT06069570
- Testing
- KB-GDT-01
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Kiromic BioPharma Inc.
Bone Metastases From Solid Tumors
Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
This is a multicenter，randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone…
- Trial name
- NCT04859569
- Testing
- LY01011, Xgeva®
- Where
- China
- Volunteers
- 850 people
- Sponsor
- Luye Pharma Group Ltd.
For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors.
- Trial name
- NCT07028268
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Bone Metastases
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04812509
- Testing
- MW032, Xgeva
- Where
- China
- Volunteers
- 708 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Fractures, Bone
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors.
- Trial name
- NCT01920568
- Testing
- Denosumab 70 mg/mL, Zoledronic acid 4 mg, Calcium supplement
- Where
- 25 sites in China, Singapore and 1 more
- Volunteers
- 487 people
- Sponsor
- GlaxoSmithKline
Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors.
- Trial name
- NCT06221072
- Testing
- JMT103, zoledronic acid
- Volunteers
- 1,360 people
- Sponsor
- Shanghai JMT-Bio Inc.